Prophylactic oral anticoagulation for atrial high rate episodes may be justified in selected patients with high stroke risk and longer episode durations (e.g., ≥24 h).
Do oral anticoagulants reduce thrombo-embolic risk in patients with atrial high rate episodes?
Prophylactic OAC treatment for AHREs remains uncertain but may be considered in high-risk patients with long AHRE durations while awaiting definitive RCT data.
Atrial high rate episodes (AHREs) are defined as asymptomatic atrial tachyarrhythmias detected by cardiac implantable electronic devices with atrial sensing, providing automated continuous monitoring and tracings storage, occurring in subjects with no previous clinical atrial fibrillation (AF) and with no AF detected at conventional electrocardiogram recordings. AHREs are associated with an increased thrombo-embolic risk, which is not negligible, although lower than that of clinical AF. The thrombo-embolic risk increases with increasing burden of AHREs, and moreover, AHREs burden shows a dynamic pattern, with tendency to progression along with time, with potential transition to clinical AF. The clinical management of AHREs, in particular with regard to prophylactic treatment with oral anticoagulants (OACs), remains uncertain and heterogeneous. At present, in patients with confirmed AHREs, as a result of device tracing analysis, an integrated, individual and clinically-guided assessment should be applied, taking into account the patients' risk of stroke (to be reassessed regularly) and the AHREs burden. The use of OACs, preferentially non-vitamin K antagonists OACs, may be justified in selected patients, such as those with longer AHREs durations (in the range of several hours or ≥24 h), with no doubts on AF diagnosis after device tracing analysis and with an estimated high/very high individual risk of stroke, accounting for the anticipated net clinical benefit, and informed patient's preferences. Two randomized clinical trials on this topic are currently ongoing and are likely to better define the role of anticoagulant therapy in patients with AHREs.
Boriani et al. (Tue,) conducted a review in Atrial high rate episodes (AHREs). Oral anticoagulants (OACs) was evaluated. Prophylactic oral anticoagulation for atrial high rate episodes may be justified in selected patients with high stroke risk and longer episode durations (e.g., ≥24 h).